Advanced alveolar soft part sarcoma responds to apatinib.
Alveolar soft part sarcoma (ASPS) is a rare, hypervascular soft tissue sarcoma with a low chemotherapy response rate. Here, we report an ASPS case with multiple lung metastases on initial presentation. The primary tumor, a hypervascular soft tissue mass 4.1×3.2×2.0 cm, located in the right thigh, was resected prior to chemotherapy. The patient suffered disease progression after two cycles of gemcitabine-docetaxel treatment. Immunohistochemical examination of the tumor tissue revealed strong positive staining for vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2). The patient was subsequently treated with apatinib (500 mg/day), a specific VEGFR-2 inhibitor. Treatment was well tolerated, and the patient exhibited a partial response, with the lung metastases reduced in size and number after one month of therapy. To date, 12-month progression-free survival has been achieved. Apatinib may provide an additional treatment option for metastatic ASPS, particularly in cases resistant to other chemotherapeutic options. Furtherstudies with more cases with longer follow-up times will be necessary to determine the clinical efficacy of apatinib for treatment of ASPS.
['Zhou|Yong|Y|', 'Tang|Fan|F|', 'Wang|Yiying|Y|', 'Min|Li|L|', 'Luo|Yi|Y|', 'Zhang|Wenli|W|', 'Shi|Rui|R|', 'Duan|Hong|H|', 'Tu|Chongqi|C|']
D000293:Adolescent D006801:Humans D008297:Male D011725:Pyridines D018234:Sarcoma, Alveolar Soft Part D012983:Soft Tissue Neoplasms
alveolar soft part sarcoma apatinib anti-angiogenesis chemotherapy resistance vascular endothelial growth factor receptor-2